

118TH CONGRESS
1ST SESSION

H. R. 5269

To amend the Federal Food, Drug, and Cosmetic Act to provide for the establishment and maintenance of a Pediatric Research Site Network.

IN THE HOUSE OF REPRESENTATIVES

AUGUST 25, 2023

Mr. CURTIS (for himself and Mr. TONKO) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to provide for the establishment and maintenance of a Pediatric Research Site Network.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Pediatric Network
5 Support Act”.

6 **SEC. 2. PEDIATRIC RESEARCH SITE NETWORK.**

7 Subchapter A of chapter V of the Federal Food,
8 Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
9 ed by adding at the end the following:

1 **“SEC. 524C. PEDIATRIC RESEARCH SITE NETWORK.**

2 “(a) ESTABLISHMENT.—The Secretary shall provide
3 for the establishment and maintenance of a Pediatric Re-
4 search Site Network in which—

5 “(1) the Secretary awards grants to eligible en-
6 tities; and

7 “(2) through such grants, the eligible entities
8 collaborate on—

9 “(A) the development and dissemination of
10 guidance and educational materials for the pur-
11 poses of—

12 “(i) enhancing pediatric clinical trials,
13 including with respect to pediatric study
14 design and feasibility;

15 “(ii) identifying and mitigating chal-
16 lenges in pediatric research that delay pe-
17 diatric clinical trials;

18 “(iii) best practices in the conduct of
19 pediatric clinical trials;

20 “(iv) improving the process for the de-
21 velopment of medical products;

22 “(v) labeling innovative medical prod-
23 ucts;

24 “(vi) accelerating medical product de-
25 velopment; and

1 “(vii) enhancing medical product safe-
2 ty; and

3 “(B) such other activities as may be deter-
4 mined by the Secretary for purposes of enhanc-
5 ing pediatric clinical trials.

6 “(b) ELIGIBLE ENTITY.—To be eligible to receive a
7 grant under this section, an entity shall meet each of the
8 following:

9 “(1) The entity is—

10 “(A) an institution of higher education as
11 defined in subsection (a) or (b) of section 101
12 of the Higher Education Act of 1965; or

13 “(B) an organization described in section
14 501(c)(3) of the Internal Revenue Code of 1986
15 and exempt from tax under section 501(a) of
16 such Code.

17 “(2) The entity has experienced personnel, and
18 clinical and other technical expertise, in the bio-
19 medical sciences.

20 “(3) The entity demonstrates to the Secretary’s
21 satisfaction that the entity is capable of carrying out
22 the activities described in subsection (a)(2).

23 “(c) ANNUAL REPORT.—Not later than 18 months
24 after the date of enactment of this section, and annually
25 thereafter, the Secretary, in collaboration with the grant-

1 ees under this section, shall submit a report to the Com-
2 mittee on Health, Education, Labor, and Pensions of the
3 Senate and the Committee on Energy and Commerce of
4 the House of Representatives—

5 “(1) reviewing the operations and activities of
6 the Pediatric Research Site Network in the previous
7 year; and

8 “(2) addressing such other issues relating to
9 this section as the Secretary determines to be appro-
10 prium.

11 “(d) DEFINITION.—In this section, the term ‘medical
12 product’ means a drug (including a biological product), a
13 device (including a diagnostic test), and any combination
14 product described in section 503(g).

15 “(e) AUTHORIZATION OF APPROPRIATIONS.—To
16 carry out this section, there is authorized to be appro-
17 priated \$2,000,000 for each of fiscal years 2024 through
18 2029.”.

○